Seidel Carina, Lenhoff Stig, Brabrand Sigmund, Anderson Gøran, Standal Therese, Lanng-Nielsen Johan, Turesson Ingemar, Børset Magne, Waage Anders
Department of IMPI, Division of Pathology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden.
Br J Haematol. 2002 Dec;119(3):672-6. doi: 10.1046/j.1365-2141.2002.03898.x.
Hepatocyte growth factor (HGF) is a cytokine produced by myeloma cells. We examined serum HGF levels in a population of young myeloma patients (median age 52 years) treated with high-dose chemotherapy. Sera from 128 myeloma patients at diagnosis and serial samples from 16 patients were analysed. Compared with 62 healthy controls, HGF was elevated at diagnosis in 25% of patients (median 0.48 and 1.08 ng/ml respectively; P < 0.0001). The 95 patients who completed therapy were analysed for the impact of HGF on survival. Median survival was not reached after 77 months in the patient group with normal HGF values (< 1.7 ng/ml, n = 69). In the group with elevated HGF (>/= 1.7 ng/ml, n = 26), median survival was 63 months (P = 0.08). In 16 patients, serum was drawn at diagnosis and at the time of expected disease remission (6 weeks to 3 months after chemotherapy). HGF values declined after treatment in 14 of these patients, from a median of 0.9 ng/ml (0.49-1.65) to 0.42 ng/ml (0.32-0.73) (P = 0.005). Our results show that in young myeloma patients HGF is elevated, and that patients with higher levels had a trend towards poorer prognosis. Treatment with high-dose chemotherapy reduced HGF in the serum of the majority of patients.
肝细胞生长因子（HGF）是一种由骨髓瘤细胞产生的细胞因子。我们检测了接受大剂量化疗的年轻骨髓瘤患者（中位年龄52岁）群体的血清HGF水平。分析了128例骨髓瘤患者诊断时的血清以及16例患者的系列样本。与62名健康对照相比，25%的患者在诊断时HGF升高（中位值分别为0.48和1.08 ng/ml；P<0.0001）。对完成治疗的95例患者分析了HGF对生存的影响。HGF值正常（<1.7 ng/ml，n=69）的患者组在77个月后未达到中位生存期。HGF升高组（≥1.7 ng/ml，n=26）的中位生存期为63个月（P=0.08）。在16例患者中，在诊断时和预期疾病缓解时（化疗后6周至3个月）采集血清。其中14例患者治疗后HGF值下降，从中位值0.9 ng/ml（0.49 - 1.65）降至0.42 ng/ml（0.32 - 0.73）（P=0.005）。我们的结果表明，年轻骨髓瘤患者中HGF升高，且水平较高的患者预后有较差的趋势。大剂量化疗使大多数患者血清中的HGF降低。
